Adlai Nortye dives in Nasdaq debut, as key product faces hurdles
Shares of the drug maker that licenses its products from other companies lost more than half their value in the two weeks after their listing Key Takeaways: Newly listed Adlai…
ANL.US
Recent Articles
RELATED ARTICLES
-
Test results for new cancer drug take Akeso investors on wild ride
9926.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
1672.HK
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
CSPC Pharma weighs up diet drug for bigger bottom line
1093.HK
Discover hidden China stock gems in our weekly newsletter